Primary biliary cholangitis

8 trials 4 recruiting MedDRA PT
8 Registered trials
4 Recruiting
6 Unique sponsors
7 Unique IMPs
7 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
A Gastroenterology (ATC A) 1
C Cardiology (ATC C) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 6 substances
Fibrate 1 substance
Phase III: 5 Phase II/III: 1 Phase II: 2

Filter these 8 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 8 trials

Phase III

5 trials
  • Glaxosmithkline Research & Development Limited Commercial
    LINERIXIBAT
    2023-503465-33-00 9 countries 2020 n=82 Orphan
    Recruiting
  • Intercept Pharmaceuticals Inc. Commercial
    BEZAFIBRATE, OBETICHOLIC ACID
    2023-507771-22-01 12 countries 2025 n=53 Orphan
    Ended
  • Ipsen Pharma Commercial
    ELAFIBRANOR
    2023-505251-43-00 14 countries 2024 n=132 Orphan
    Recruiting
  • Ipsen Pharma Commercial
    ELAFIBRANOR
    2024-510695-20-00 7 countries 2024 n=35 Orphan
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    BEZAFIBRATE
    2023-504086-23-00 1 country 2025 n=130
    Recruiting

Phase II/III

1 trial
  • Zydus Therapeutics Inc. Commercial
    SAROGLITAZAR HEMIMAGNESIUM
    2024-518718-14-00 1 country 2023 n=6
    Ended

Phase II

2 trials
  • Intercept Pharmaceuticals Inc. Commercial
    BEZAFIBRATE; OBETICHOLIC ACID
    2024-513584-77-00 1 country 2023 n=5 Orphan
    Ended
  • Mirum Pharmaceuticals Inc. Commercial
    VOLIXIBAT
    2023-504660-41-00 6 countries 2022 n=84 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Intercept Pharmaceuticals Inc. Commercial 2 Phase II, Phase III 0
Ipsen Pharma Commercial 2 Phase III 1
Zydus Therapeutics Inc. Commercial 1 Phase II/III 0
Mirum Pharmaceuticals Inc. Commercial 1 Phase II 1
Glaxosmithkline Research & Development Limited Commercial 1 Phase III 1
Assistance Publique Hopitaux De Paris Academic 1 Phase III 1
New trials by year
2020
1
2022
1
2023
2
2024
2
2025
2
← All indication landscapes